**RiTUXimab and Bendamustine Therapy**

**INDICATIONS FOR USE:**

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Protocol Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of patients with previously untreated indolent CD20-positive,</td>
<td>C82</td>
<td>00345a</td>
</tr>
<tr>
<td>stage III-IV non-hodgkin lymphoma (NHL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of patients with previously untreated CD20-positive, stage</td>
<td>C83</td>
<td>00345b</td>
</tr>
<tr>
<td>III-IV mantle cell lymphoma (MCL), ineligible for autologous stem cell</td>
<td></td>
<td></td>
</tr>
<tr>
<td>transplant</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ELIGIBILITY:**
- Indications as above
- ECOG status 0-2

**EXCLUSIONS:**
- Hypersensitivity to bendamustine, RiTUXimab or any of the excipients or to murine proteins.
- Active, severe infections (e.g. tuberculosis, sepsis and opportunistic infections)
- Patients in a severely immunocompromised state.
- AST or ALT greater than 2.5 x upper limit of normal and total bilirubin greater than 1.5 x upper limit of normal
- Severe bone marrow suppression and severe blood count alterations (leukocyte and/or platelet values dropped to < 3 x 10^9/L or < 75x 10^9/L, respectively)

**TESTS:**

- **Baseline tests:**
  - FBC, U&Es, LFTs, LDH
  - ECG
  - Virology screen - Hepatitis B (HBsAg, HBcoreAb) & C, HIV

**Hepatitis B:**
All lymphoma patients should be tested for both HBsAg and HBcoreAb. If either test is positive, such patients should be treated with lamivudine 100 mg/day orally, for the entire duration of chemotherapy and for six months afterwards (Refer to local policy). Such patients should also be monitored with frequent liver function tests and hepatitis B monitoring.

---

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician. and is subject to HSE’s terms of use available at [http://www.hse.ie/eng/Disclaimer](http://www.hse.ie/eng/Disclaimer).

This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoprotocols](http://www.hse.ie/NCCPchemoprotocols).
B virus DNA at least every two months. If the hepatitis B virus DNA level rises during this monitoring, management should be reviewed with an appropriate specialist with experience managing hepatitis and consideration given to stopping chemotherapy.  
*See Adverse Effects/Regimen Specific Complications

Regular tests:
FBC, U&Es, LFTs, LDH
ECG as clinically indicated (See Adverse Events/Regimen Specific Complications)

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

TREATMENT:
*The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.*

Bendamustine is administered on day 1 and day 2 and riTUXimab on day 1 of a 28 day cycle for up to 6 cycles or until disease progression or unacceptable toxicity develops.

Facilities to treat anaphylaxis MUST be present when riTUXimab therapy is administered.
# NCCP Chemotherapy Protocol

## Day 1
- **Drug**: RitUXimab
- **Dose**: 375mg/m²
- **Route and Method of Administration**: IV infusion
- **Diluent & Rate**: 250 to 500ml 0.9% sodium chloride at a maximum rate of 400mg/hr
- **Cycle**: 1-6

### Notes:
- The recommended initial rate for infusion is 50 mg/hr; after the first 30 minutes, it can be escalated in 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
- Subsequent infusions can be infused at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr.
- Development of an allergic reaction may require a slower infusion rate. See Hypersensitivity/Infusion reactions under Adverse Effects/Regimen Specific Complications below.
- Any deviation from the advised infusion rate should be noted in local policies.

## Day 1 and 2
- **Drug**: Bendamustine
- **Dose**: 90mg/m²
- **Route and Method of Administration**: IV infusion
- **Diluent & Rate**: 250 to 500 mL NS over 1 hour
- **Cycle**: 1-6

### Notes:
- Recommended Observation period: Patients should be observed for at least six hours after the start of the first infusion and for two hours after the start of the subsequent infusions for symptoms like fever and chills or other infusion-related symptoms. Any deviation should be noted in local policies.
- Rituximab should be diluted to a final concentration of 1-4mg/ml.
- Rapid rate infusion schedule:
  - If patients did not experience a serious infusion related reaction with their first or subsequent infusions of a dose of RitUXimab administered over the standard infusion schedule, a more rapid infusion can be administered for second and subsequent infusions using the same concentration as in previous infusions. Initiate at a rate of 20% of the total dose for the first 30 minutes and then 80% of the dose for the next 60 minutes (total infusion time of 90 minutes). If the more rapid infusion is tolerated, this infusion schedule can be used when administering subsequent infusions.
  - Patients who have clinically significant cardiovascular disease, including arrhythmias, or previous serious infusion reactions to any prior biologic therapy or to RitUXimab, should not be administered the more rapid infusion.

## DOSE MODIFICATIONS:
- Any dose modification should be discussed with a Consultant
- No dose reductions of RitUXimab are recommended.

<table>
<thead>
<tr>
<th>ANC ( x 10⁹/L)</th>
<th>Platelets( x 10⁹/L)</th>
<th>Dose of Bendamustine</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥1 and ≥75</td>
<td>≤75</td>
<td>100%</td>
</tr>
<tr>
<td>&lt; 1 or &lt; 75</td>
<td></td>
<td>Delay until recovery</td>
</tr>
</tbody>
</table>

---

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician. and is subject to HSE’s terms of use available at [http://www.hse.ie/eng/Disclaimer](http://www.hse.ie/eng/Disclaimer).

This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoprotocols](http://www.hse.ie/NCCPchemoprotocols).
Renal and Hepatic Dysfunction:

Table 1: Dose modification schedule for riTUXimab based on adverse events

<table>
<thead>
<tr>
<th>Adverse reactions</th>
<th>Discontinue</th>
<th>Recommended dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe infusion related reaction</td>
<td>Discontinue</td>
<td>Interrupt infusion immediately. Evaluate for cytokine release/tumour lysis syndrome (appropriate laboratory tests) and pulmonary infiltration (chest x-ray). Infusion may be restarted on resolution of all symptoms, normalisation of laboratory values and chest x-ray findings at no more than one-half the previous rate.</td>
</tr>
<tr>
<td>First occurrence</td>
<td>Discontinue</td>
<td>Consider coverage with steroids for those who are not already receiving steroids.</td>
</tr>
<tr>
<td>First occurrence</td>
<td>Consider discontinuing treatment</td>
<td>Reduce rate of infusion. The infusion rate may be increased upon improvement of symptoms</td>
</tr>
</tbody>
</table>

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:
Rituximab Low (Refer to local policy).
Bendamustine Moderate (Refer to local policy)

PREMEDICATIONS:
Premedication consisting of an anti-pyretic and an anti-histamine should always be administered before each infusion of riTUXimab. Premedication with glucocorticoids should be considered if riTUXimab is not given in combination with glucocorticoids containing chemotherapy for treatment of NHL.
### Table 2: Suggested pre-medications prior to riTUXimab infusion:

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Dose</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paracetamol</td>
<td>1g</td>
<td>PO</td>
</tr>
<tr>
<td>Chlorpheniramine</td>
<td>10mg</td>
<td>IV bolus</td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>100mg</td>
<td>IV bolus, 30-60 minutes before riTUXimab</td>
</tr>
</tbody>
</table>

### TAKE HOME MEDICATIONS:
Not usually required.

### OTHER SUPPORTIVE CARE:
- Tumour lysis syndrome prophylaxis ([Refer to local policy](#))
- PJP prophylaxis ([Refer to local policy](#))
- Proton Pump Inhibitor ([Refer to local policy](#))
- Anti-viral prophylaxis ([Refer to local policy](#))
- Anti-fungal prophylaxis ([Refer to local policy](#))

### ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS
The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Hypersensitivity/Infusion Reactions**: Close monitoring is required throughout the first infusion of riTUXimab (See Table 1 for modifications in the event of an infusion reaction).

  Bendamustine can cause allergic type reactions during the IV infusion such as fever, chills, pruritus and rash. Severe anaphylactic and anaphylactoid reactions have occurred rarely, particularly in the second and subsequent cycles of therapy. If an allergic reaction occurs, stop the infusion and the physician in charge should determine a safe time and rate to resume the infusion. Consider pre-treatment with antihistamines, antipyretics and corticosteroids for patients experiencing Grade 1 or 2 infusion reactions; consider discontinuing treatment for patients experiencing Grade 3 or 4 infusion reactions.

- **Cardiac Disorders**: Patients with a history of cardiac disease and/or cardiotoxic chemotherapy should be monitored closely. During treatment with bendamustine...
hydrochloride the concentration of potassium in the blood must be closely monitored and potassium supplement must be given when K+ <3.5 mEq/l, and ECG measurement must be performed.

- **Skin reactions:** A number of skin reactions have been reported with bendamustine therapy. These events have included rash, toxic skin reactions and bullous exanthema. Some events occurred when bendamustine hydrochloride was given in combination with other anticancer agents, so the precise relationship is uncertain. Where skin reactions occur, they may be progressive and increase in severity with further treatment. If skin reactions are progressive, bendamustine should be withheld or discontinued. For severe skin reactions where a relationship to bendamustine hydrochloride is suspected, treatment should be discontinued.

- **Severe Cytokine Release syndrome:** Usually occurs within 1 to 2 hours of initiating the first infusion of riTUXimab. This syndrome may be associated with some features of cytokine release/tumour lysis syndrome such as hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphatemia, acute renal failure, elevated lactate dehydrogenase (LDH) and may be associated with acute respiratory failure and death.
  - Pulmonary interstitial infiltrates or oedema visible on chest x-ray may accompany acute respiratory failure.
  - For severe reactions, stop the infusion immediately and evaluate for tumour lysis syndrome and pulmonary infiltration. Aggressive symptomatic treatment is required. The infusion can be resumed at no more than one-half the previous rate once all symptoms have resolved, and laboratory values and chest x-ray findings have normalized.

- **Severe Mucocutaneous Reactions:** These include Steven Johnson syndrome and toxic epidermal necrolysis. Discontinue riTUXimab in patients who develop a severe mucocutaneous reaction. The safety of readministration has not been determined.

- **Progressive multifocal leukoencephalopathy (PML):** Use of riTUXimab may be associated with an increased risk of PML. Patients must be monitored for any new or worsening neurological symptoms.

- **Infections:** RiTUXimab should not be administered to patients with an active, severe infection. Caution should be exercised when considering the use of riTUXimab in patients with a history of recurring or chronic infections or with underlying conditions which may further predispose patients to serious infections. Consideration should be given to the use of antimicrobial prophylaxis.

- **Tumour lysis syndrome:** Tumour lysis syndrome associated with bendamustine treatment has been reported in patients in clinical trials. The onset tends to be within 48 hours of the first dose of bendamustine and, without intervention, may lead to
acute renal failure and death. Preventive measures include adequate volume status and close monitoring of blood chemistry, particularly potassium and uric acid levels. The use of allopurinol during the first one to two weeks of bendamustine therapy can be considered but not necessarily as standard. However, there have been a few cases of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis reported when bendamustine and allopurinol were administered concomitantly.

- **Vaccines:** Physicians should review the patient’s vaccination status and follow current immunisation guidelines prior to rituximab therapy. Vaccination should be completed at least 4 weeks prior to first administration of rituximab.
  - The safety of immunisation with live viral vaccines following rituximab therapy has not been studied. Therefore vaccination with live virus vaccines is not recommended whilst on rituximab or whilst peripherally B cell depleted.
  - Patients treated with rituximab may receive non-live vaccinations

- **Fertility:** Women of childbearing potential must use effective methods of contraception both before and during bendamustine therapy. Men being treated with bendamustine are advised not to father a child during and for up to 6 months following cessation of treatment. Advice on conservation of sperm should be sought prior to treatment because of the possibility of irreversible infertility due to therapy with bendamustine.

**DRUG INTERACTIONS:**
- **Antihypertensives:** Additive effect of hypotension during rituximab infusion. Consider withholding antihypertensives 12 hours before and during rituximab infusion.
- **Bendamustine** metabolism involves cytochrome P450 (CYP) 1A2 isoenzyme. Therefore, the potential for interaction with CYP1A2 inhibitors such as fluvoxamine, ciprofloxacin, acyclovir and cimetidine exists.
- Current drug interaction databases should be consulted for more information

**ATC CODE:**
- RitUXimab - L01XC02
- Bendamustine - L01AA09

**REIMBURSEMENT CATEGORY:**
RitUXimab and bendamustine are funded through local hospital budgets (Jan 2017).
**PRESCRIPTIVE AUTHORITY:**
The treatment plan must be initiated by a Consultant Medical Oncologist or Consultant Haematologist experienced in the treatment of haematological malignancies.

**REFERENCES:**


<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Amendment</th>
<th>Approved By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>05/04/2017</td>
<td></td>
<td>Prof E Vandenberghe Prof Maccon Keane</td>
</tr>
</tbody>
</table>

NCCP Protocol: RiTUXimab and Bendamustine Therapy

Published: 05/04/2017
Review: 05/04/2019

Tumour Group: Lymphoma and Myeloma

NCCP Protocol Code: 00345

IHS Contributor: Prof E Vandenberghe
ISMO Contributor: Prof Maccon Keane

Version number: 1

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician. and is subject to HSE’s terms of use available at [http://www.hse.ie/eng/Disclaimer](http://www.hse.ie/eng/Disclaimer)

This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoprotocols](http://www.hse.ie/NCCPchemoprotocols)
NCCP Chemotherapy Protocol

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

The rapid infusion is an unlicensed means of administration of rituximab for the indications described above, in Ireland. Patient’s should be informed of this and consented to treatment in line with the hospital’s policy on the use of unlicensed medication and unlicensed or “off label” indications. Prescribers should be fully aware of their responsibility in communicating any relevant information to the patient and also ensuring that the unlicensed or “off label” means of administration has been acknowledged by the hospital’s Drugs and Therapeutics Committee, or equivalent, in line with hospital policy.